Advanced Biomed出售香港子公司应对监管变化，股价波动显著

Core Viewpoint - Advanced Biomed Inc. has made a significant asset sale, resulting in notable stock price volatility, while the company's fundamentals remain in a state of no revenue generation and ongoing losses [1]. Recent Events - On December 23, 2025, the company signed an agreement to sell 100% of its wholly-owned subsidiary Advanced Biomed (HK) Limited for a total consideration of $23,000, which includes all intellectual property owned by the subsidiary. The CEO stated that this sale is part of a strategic adjustment to respond to changes in the regulatory environment in China, with future clinical trials to be focused on the Taiwan subsidiary [2]. Stock Performance - The stock exhibited high volatility from December 2025 to early January 2026. For instance, on December 26, 2025, the stock price dropped by 11.44%, while on January 5, 2026, it rebounded with a 5.26% increase. This volatility may reflect market reactions to the company's actions and overall trading sentiment [3]. Financial Performance - According to the latest financial report, the company reported zero revenue, a net loss of $12,925.94, earnings per share of $0, and a negative price-to-earnings ratio ranging from -1.89 to -2.14, indicating that the company is still in a state of no revenue generation and losses [4]. Institutional Views - As of January 8, 2026, there are no institutional investment ratings or recommendations available for the stock [5].